Articles
Driver Faces Charges Following Fatal Crash Involving Boxer Anthony Joshua in Nigeria
Legal proceedings underway after collision on Lagos-Ibadan Expressway results in two deaths and injury to heavyweight champion Joshua
Authorities in Ogun state, Nigeria have formally charged Adeniyi Mobolaji Kayode, the driver involved in a traffic accident that led to the death of t...
AMC Entertainment Sees Notable Uptick Following Netflix Collaboration
Strategic Partnership Drives Theater Attendance and Food & Beverage Revenue
AMC Entertainment Holdings Inc. experienced a surge in customer attendance linked to its collaboration with Netflix during the premiere of the Strange...
Upgrade to Buy: Nvidia After the $20B Groq Chatter - Growth, Margins, and a Measured Trade Plan
Strong FY26 quarters, cash generation, and an (as-yet-unverified) Groq deal justify raising the rating — but valuation and geopolitical risk demand tight risk management.
Nvidia's latest quarters show accelerating revenue and profit, industry-leading margins, and large free cash flow. Reports of a roughly $20B deal to a...
Coinbase Sets Ambitious 2026 Goals Amid Stock Price Challenges
CEO Brian Armstrong Outlines Expansion Strategy Into Tokenized Markets and Stablecoin Adoption While Stock Faces Key Technical Support
Coinbase Global Inc. CEO Brian Armstrong has articulated a comprehensive strategy for 2026 aimed at transforming the company into the foremost financi...
Yum China (YUMC): Buy on Durable Cash Flow, Dividend Cushion and Attractive ~17x Run‑Rate P/E
Operational momentum in China, steady cash generation and rising shareholder returns make YUMC a tactical buy with a clear risk-management plan.
Yum China is the largest restaurant operator in China with >18,000 units and $12bn systemwide sales in 2025. Recent quarters show consistent revenue a...
Casgevy Is the Make-or-Break Catalyst for CRISPR Therapeutics in 2026
A position trade: buy the commercialization optionality, manage binary regulatory/commercial risk
CRISPR Therapeutics (CRSP) has moved from pure R&D to a commercial-stage company with the approval of Casgevy. The stock is trading near $53 (01/02/20...
Hut 8 Corporation Exhibits Strong Technical Momentum Alongside Recent Analyst Endorsements
Robust Analyst Price Target Increases and Favorable Technical Indicators Signal Investor Optimism for Cryptocurrency Miner
Hut 8 Corporation's stock has gained notable upward traction, buoyed by significant analyst upgrades and a positive technical setup. The company's sha...
ParaZero Technologies Secures Strategic Defense Contract, Propelling Stock Surge
Breakthrough Israeli Defense Order for Anti-Drone System Drives Investor Interest
ParaZero Technologies Ltd. experienced a significant increase in its stock value following its announcement of a substantial purchase order from a pro...
BigBear.ai Advances Strategic Footprint with Major Acquisition and Regional Expansion
Company bolsters AI defense capabilities and enters Middle Eastern market amid rising investor interest
BigBear.ai, a leader in artificial intelligence solutions for national security and commercial sectors, has recently made strategic moves that have ca...
Building and Using a Stock Trading Journal: A Comprehensive Guide for Systematic Self-Improvement
For beginner and intermediate traders seeking to enhance discipline, identify patterns, and refine their trading through structured journaling
A well-maintained trading journal is one of the most powerful tools traders can use to develop discipline and improve consistency. This guide covers w...
Strategies to Enhance Your Social Security Income Following an Early Claim
Exploring actionable options for recipients who started benefits before reaching full retirement age
Claiming Social Security benefits early leads to a reduced monthly payment based on how far ahead of full retirement age (FRA) the claim occurs. Howev...
Verastem Oncology Shifts Focus After Halting KRAS G12C Lung Cancer Trial
Company Redirects Efforts Toward Promising KRAS G12D Inhibitor Amid Intensifying Competition
Verastem Oncology has decided to discontinue enrollment in its RAMP 203 clinical trial targeting advanced non-small cell lung cancer (NSCLC) with KRAS...